Mineralys Therapeutics Inc (MLYS) FinancialsMLYSMineralys Therapeutics Inc

Evaluating the bottom line, Mineralys Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.88%, provide a clear picture of how effectively MLYS converts its operational activities into shareholder value.

In the context of the broader market, MLYS competes directly with industry leaders such as NVAX and PVLA. With a market capitalization of $1.84B, it holds a significant position in the sector. When comparing efficiency, MLYS's gross margin of N/A stands against NVAX's 78.93% and PVLA's N/A. Such benchmarking helps identify whether Mineralys Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Mineralys has been experiencing substantial net losses, with Q2 2026 showing a loss of $241 million. The current ratio is strong at 34.46, indicating good short-term liquidity, but the overall financial performance is concerning due to the ongoing losses.